Mark O’Connor

Company: AstraZeneca

Job title: Chief Scientist, Early Oncology Discovery

Seminars:

Panel Discussion: DDR Inhibitors & the Immune Response Interface 12:15 pm

DNA damage checkpoint activation, inducing the expression of antimicrobial peptides and activating immune cell receptor ligands: what are the ways DDRis impact these immune responses Which pathways within DDR are involved in immune signalling? DNA damage and chronic inflammation: what is the link?Read more

day: Day One

Combining Inhibitors of the DNA Damage Response Pathway with Immunotherapies to Treat Cancer 11:15 am

The multiple interfaces between the DDR and the immune response PARP inhibitor immune priming in BRCA deficient cancers The link between ATR inhibition, replication stress and the ability to overcome immunotherapy resistanceRead more

day: Day One